The government has directed manufacturers to lower prices of Trastuzumab, Osimertinib, and Durvalumab after exempting them from customs duty and reducing GST. This measure aims to ensure affordable anti-cancer drugs for consumers. Companies must update and report new prices to authorities and dealers.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/L8xRb4u
via IFTTT
No comments:
Post a Comment